To Evaluate Safety and Tolerability of the Fixed- Dose Combination of Obeticholic Acid and Bezafibrate
NCT ID: NCT06488911
Last Updated: 2025-10-31
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
TERMINATED
PHASE3
63 participants
INTERVENTIONAL
2024-07-01
2025-10-21
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Study of OCA in Combination With BZF Evaluating Efficacy, Safety, and Tolerability in Participants With PBC
NCT04594694
Study of OCA in Combination With BZF Evaluating Efficacy, Safety and Tolerability in Participants With PBC
NCT05239468
A Real-World Data Study to Evaluate the Effectiveness of OCA on Hepatic Outcomes in PBC Patients
NCT05293938
Phase 4 Study of Obeticholic Acid Evaluating Clinical Outcomes in Patients With Primary Biliary Cholangitis
NCT02308111
Use of Bezafibrate in Patients With Primary Biliary Cirrhosis to Archive Complete Biochemical Response in Non-responders
NCT02937012
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NA
SINGLE_GROUP
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
OCA 5 mg + BZF 400 mg SR
Participants will be administered with OCA 5 mg + BZF 400 mg SR once daily.
FDC tablet (OCA 5 mg + BZF 400 mg SR)
Participants will be administered with FDC tablets once daily.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
FDC tablet (OCA 5 mg + BZF 400 mg SR)
Participants will be administered with FDC tablets once daily.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
* Clinical complications of PBC
* History or presence of hepatic decompensating events
* Current or history of gallbladder disease
* If female, known pregnancy, or has a positive urine pregnancy test (confirmed by a positive serum pregnancy test), or lactating.
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Intercept Pharmaceuticals
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Lynda Szczech, PhD
Role: STUDY_DIRECTOR
Intercept Pharmaceuticals Inc.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
University of Alabama at Birmingham
Birmingham, Alabama, United States
Southern California Research Center
Coronado, California, United States
Tampa General Medical Group
Tampa, Florida, United States
Piedmont Atlanta Hospital
Atlanta, Georgia, United States
Ochsner Clinic Foundation
New Orleans, Louisiana, United States
Beth Israel Deaconess Medical Center
Boston, Massachusetts, United States
NYU Langone Health
New York, New York, United States
University Hospitals Cleveland Medical Center
Cleveland, Ohio, United States
Gastro One
Germantown, Tennessee, United States
East Tennessee Research Institute
Johnson City, Tennessee, United States
The Liver Institute at Methodist Dallas Medical Center
Dallas, Texas, United States
Houston Methodist Hospital
Houston, Texas, United States
American Research Corporation
San Antonio, Texas, United States
DIM Clinica Privada
Buenos Aires, , Argentina
Hospital Italiano de Buenos Aires
Buenos Aires, , Argentina
Hospital Italiano de La Plata
Buenos Aires, , Argentina
Hospital Universitario Austral
Buenos Aires, , Argentina
Hospital Provincial del Centenario
Santa Fe, , Argentina
Royal Adelaide Hospital
Adelaide, , Australia
Flinders Medical Centre
Bedford Park, , Australia
UZ Leuven
Leuven, , Belgium
University of Alberta Division of Gastroenterology Zeidler Ledcor Centre
Edmonton, Alberta, Canada
Pacific Gastroenterology Associates GI Research Institute
Vancouver, British Columbia, Canada
Universityl Hospital Dubrava
Zagreb, , Croatia
Hepato-Gastroenterologie HK, s.r.o.
Hradec Králové, , Czechia
Artroscan s.r.o. Gastroenterologicka
Ostrava, , Czechia
Research Site SRO
Pilsen, , Czechia
Tartu University Hospital
Tartu, , Estonia
Hopital Henri Mondor
Créteil, , France
CHRU de Lille
Lille, , France
CHU Paris Est - Hopital Saint Antoine
Paris, , France
Hopital de la Pitie Salpetriere
Paris, , France
Medizinische Hochschule Hannover
Hanover, , Germany
University Hospital of Larissa
Larissa, , Greece
DEOEC II. sz. Belgygyszati Klinika
Debrecen, , Hungary
Hadassah Ein-Karem Medical Center - Liver unit
Jerusalem, , Israel
Azienda Ospedaliero-Universitaria di Bologna Policlinico S. Orsola-Malpighi
Bologna, , Italy
University Hopital Santaros klinikos
Vilnius, , Lithuania
Academisch Medisch Centrum
Amsterdam, , Netherlands
Akershus University Hospital
Lørenskog, , Norway
Kyungpook National University Hospital
Daegu, , South Korea
Seoul National University Bundang Hospital
Seongnam-si, , South Korea
Hospital ClinicUniversity of Barcelona
Barcelona, , Spain
Consorcio Hospital General Universitario
Valencia, , Spain
Hacettepe University, Faculty of Medicine, Adult Hospital Gastroenterology
Ankara, , Turkey (Türkiye)
Ege University, Faculty of Medicine, Gastroenterology
Bornova, , Turkey (Türkiye)
Istanbul University, Capa Faculty of Medicine, Gastroenterology
Istanbul, , Turkey (Türkiye)
Harran University Hospital, Gastroenterology
Sanliurfa, , Turkey (Türkiye)
Hull University Teaching Hospitals NHS Trust
Hull, , United Kingdom
Institute of Cellular Medicine Newcastle University
Newcastle upon Tyne, , United Kingdom
John Radcliffe Hospital
Oxford, , United Kingdom
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
977-311
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.